ATP-competitive JNK inhibitors have been crucial for delineating and defining our understanding of JNK signaling in tumorigenesis, with the anthrapyrazole inhibitor SP600125 amongst the most commonly used in experimental cancer models [19] (Figure 2B-i). This evidence concerns the gene MAPK8 and cancer.